139 related articles for article (PubMed ID: 37685815)
1. External Validation of the IMPROD-MRI Volumetric Model to Predict the Utility of Systematic Biopsies at the Time of Targeted Biopsy.
Ninivaggi A; Guzzi F; Degennaro A; Ricapito A; Bettocchi C; Busetto GM; Sanguedolce F; Milillo P; Selvaggio O; Cormio L; Carrieri G; Falagario UG
J Clin Med; 2023 Sep; 12(17):. PubMed ID: 37685815
[No Abstract] [Full Text] [Related]
2. Added value of systematic biopsy in men with a clinical suspicion of prostate cancer undergoing biparametric MRI-targeted biopsy: multi-institutional external validation study.
Falagario U; Jambor I; Taimen P; Syvänen KT; Kähkönen E; Merisaari H; Montoya Perez I; Knaapila J; Steiner A; Verho J; Tewari A; Aronen HJ; Carrieri G; Boström PJ; Ettala O
World J Urol; 2021 Jun; 39(6):1879-1887. PubMed ID: 32778912
[TBL] [Abstract][Full Text] [Related]
3. Negative Predictive Value of Biparametric Prostate Magnetic Resonance Imaging in Excluding Significant Prostate Cancer: A Pooled Data Analysis Based on Clinical Data from Four Prospective, Registered Studies.
Knaapila J; Jambor I; Ettala O; Taimen P; Verho J; Perez IM; Kiviniemi A; Pahikkala T; Merisaari H; Lamminen T; Saunavaara J; Aronen HJ; Syvänen KT; Boström PJ
Eur Urol Focus; 2021 May; 7(3):522-531. PubMed ID: 32418878
[TBL] [Abstract][Full Text] [Related]
4. A 4K score/MRI-based nomogram for predicting prostate cancer, clinically significant prostate cancer, and unfavorable prostate cancer.
Wagaskar VG; Sobotka S; Ratnani P; Young J; Lantz A; Parekh S; Falagario UG; Li L; Lewis S; Haines K; Punnen S; Wiklund P; Tewari A
Cancer Rep (Hoboken); 2021 Aug; 4(4):e1357. PubMed ID: 33661541
[TBL] [Abstract][Full Text] [Related]
5. There Is No Way to Avoid Systematic Prostate Biopsies in Addition to Multiparametric Magnetic Resonance Imaging Targeted Biopsies.
Dell'Oglio P; Stabile A; Soligo M; Brembilla G; Esposito A; Gandaglia G; Fossati N; Bravi CA; Dehò F; De Cobelli F; Montorsi F; Karnes RJ; Briganti A
Eur Urol Oncol; 2020 Feb; 3(1):112-118. PubMed ID: 31411973
[TBL] [Abstract][Full Text] [Related]
6. Clinical Utility of Negative Multiparametric Magnetic Resonance Imaging in the Diagnosis of Prostate Cancer and Clinically Significant Prostate Cancer.
Wagaskar VG; Levy M; Ratnani P; Moody K; Garcia M; Pedraza AM; Parekh S; Pandav K; Shukla B; Prasad S; Sobotka S; Haines K; Punnen S; Wiklund P; Tewari A
Eur Urol Open Sci; 2021 Jun; 28():9-16. PubMed ID: 34337520
[TBL] [Abstract][Full Text] [Related]
7. Head-to-head Comparison of Transrectal Ultrasound-guided Prostate Biopsy Versus Multiparametric Prostate Resonance Imaging with Subsequent Magnetic Resonance-guided Biopsy in Biopsy-naïve Men with Elevated Prostate-specific Antigen: A Large Prospective Multicenter Clinical Study.
van der Leest M; Cornel E; Israël B; Hendriks R; Padhani AR; Hoogenboom M; Zamecnik P; Bakker D; Setiasti AY; Veltman J; van den Hout H; van der Lelij H; van Oort I; Klaver S; Debruyne F; Sedelaar M; Hannink G; Rovers M; Hulsbergen-van de Kaa C; Barentsz JO
Eur Urol; 2019 Apr; 75(4):570-578. PubMed ID: 30477981
[TBL] [Abstract][Full Text] [Related]
8. Predicting Benign Prostate Pathology on Magnetic Resonance Imaging/Ultrasound Fusion Biopsy in Men with a Prior Negative 12-core Systematic Biopsy: External Validation of a Prognostic Nomogram.
Bjurlin MA; Renson A; Rais-Bahrami S; Truong M; Rosenkrantz AB; Huang R; Taneja SS
Eur Urol Focus; 2019 Sep; 5(5):815-822. PubMed ID: 29802053
[TBL] [Abstract][Full Text] [Related]
9. Prostate cancer detection rate in men undergoing transperineal template-guided saturation and targeted prostate biopsy.
Kaufmann B; Saba K; Schmidli TS; Stutz S; Bissig L; Britschgi AJ; Schaeren E; Gu A; Langenegger N; Sulser T; Eberli D; Keller EX; Hermanns T; Poyet C
Prostate; 2022 Feb; 82(3):388-396. PubMed ID: 34914121
[TBL] [Abstract][Full Text] [Related]
10. Prostate Cancer Risk Assessment in Biopsy-naïve Patients: The Rotterdam Prostate Cancer Risk Calculator in Multiparametric Magnetic Resonance Imaging-Transrectal Ultrasound (TRUS) Fusion Biopsy and Systematic TRUS Biopsy.
Mannaerts CK; Gayet M; Verbeek JF; Engelbrecht MRW; Savci-Heijink CD; Jager GJ; Gielens MPM; van der Linden H; Beerlage HP; de Reijke TM; Wijkstra H; Roobol MJ
Eur Urol Oncol; 2018 Jun; 1(2):109-117. PubMed ID: 31100233
[TBL] [Abstract][Full Text] [Related]
11. Qualitative and Quantitative Reporting of a Unique Biparametric MRI: Towards Biparametric MRI-Based Nomograms for Prediction of Prostate Biopsy Outcome in Men With a Clinical Suspicion of Prostate Cancer (IMPROD and MULTI-IMPROD Trials).
Perez IM; Jambor I; Kauko T; Verho J; Ettala O; Falagario U; Merisaari H; Kiviniemi A; Taimen P; Syvänen KT; Knaapila J; Seppänen M; Rannikko A; Riikonen J; Kallajoki M; Mirtti T; Lamminen T; Saunavaara J; Pahikkala T; Boström PJ; Aronen HJ
J Magn Reson Imaging; 2020 May; 51(5):1556-1567. PubMed ID: 31750988
[TBL] [Abstract][Full Text] [Related]
12. Prebiopsy IMPROD Biparametric Magnetic Resonance Imaging Combined with Prostate-Specific Antigen Density in the Diagnosis of Prostate Cancer: An External Validation Study.
Knaapila J; Jambor I; Perez IM; Ettala O; Taimen P; Verho J; Kiviniemi A; Pahikkala T; Merisaari H; Lamminen T; Saunavaara J; Aronen HJ; Syvänen KT; Boström PJ
Eur Urol Oncol; 2020 Oct; 3(5):648-656. PubMed ID: 31501082
[TBL] [Abstract][Full Text] [Related]
13. Magnetic Resonance Imaging-targeted Prostate Biopsy Compared with Systematic Prostate Biopsy in Biopsy-naïve Patients with Suspected Prostate Cancer.
Alkema NG; Hoogeveen SFJS; Cauberg ECC; Witte LPW; van 't Veer-Ten Kate M; de Boer E; Hoogland MAM; Blanker MH; Boomsma MF; Steffens MG
Eur Urol Open Sci; 2022 Oct; 44():125-130. PubMed ID: 36185584
[TBL] [Abstract][Full Text] [Related]
14. Can we omit systematic biopsies in patients undergoing MRI fusion-targeted prostate biopsies?
Leow JJ; Koh SH; Chow MW; Loke W; Salada R; Hong SK; Yeow Y; Lee CH; Tan CH; Tan TW
Asian J Androl; 2023; 25(1):43-49. PubMed ID: 35488666
[TBL] [Abstract][Full Text] [Related]
15. The Added Value of Side-specific Systematic Biopsy in Patients Diagnosed by Magnetic Resonance Imaging-targeted Prostate Biopsy.
Bourgeno HA; Jabbour T; Baudewyns A; Lefebvre Y; Ferriero M; Simone G; Fourcade A; Fournier G; Oderda M; Gontero P; Bernal-Gomez A; Mastrorosa A; Roche JB; Abou Zahr R; Ploussard G; Fiard G; Halinski A; Rysankova K; Dariane C; Delavar G; Anract J; Barry Delongchamps N; Bui AP; Taha F; Windisch O; Benamran D; Assenmacher G; Vlahopoulos L; Guenzel K; Roumeguère T; Peltier A; Diamand R
Eur Urol Oncol; 2024 Jan; ():. PubMed ID: 38272745
[TBL] [Abstract][Full Text] [Related]
16. Predicting the Need for Biopsy to Detect Clinically Significant Prostate Cancer in Patients with a Magnetic Resonance Imaging-detected Prostate Imaging Reporting and Data System/Likert ≥3 Lesion: Development and Multinational External Validation of the Imperial Rapid Access to Prostate Imaging and Diagnosis Risk Score.
Peters M; Eldred-Evans D; Kurver P; Falagario UG; Connor MJ; Shah TT; Verhoeff JJC; Taimen P; Aronen HJ; Knaapila J; Montoya Perez I; Ettala O; Stabile A; Gandaglia G; Fossati N; Martini A; Cucchiara V; Briganti A; Lantz A; Picker W; Haug ES; Nordström T; Tanaka MB; Reddy D; Bass E; van Rossum PSN; Wong K; Tam H; Winkler M; Gordon S; Qazi H; Boström PJ; Jambor I; Ahmed HU
Eur Urol; 2022 Nov; 82(5):559-568. PubMed ID: 35963650
[TBL] [Abstract][Full Text] [Related]
17. Combined Use of Prostate-specific Antigen Density and Magnetic Resonance Imaging for Prostate Biopsy Decision Planning: A Retrospective Multi-institutional Study Using the Prostate Magnetic Resonance Imaging Outcome Database (PROMOD).
Falagario UG; Jambor I; Lantz A; Ettala O; Stabile A; Taimen P; Aronen HJ; Knaapila J; Perez IM; Gandaglia G; Fossati N; Martini A; Cucchiara V; Picker W; Haug E; Ratnani P; Haines K; Lewis S; Sujit N; Selvaggio O; Sanguedolce F; Macarini L; Cormio L; Nordström T; Tewari A; Briganti A; Boström PJ; Carrieri G
Eur Urol Oncol; 2021 Dec; 4(6):971-979. PubMed ID: 32972896
[TBL] [Abstract][Full Text] [Related]
18. The "Is mpMRI Enough" or IMRIE Study: A Multicentre Evaluation of Prebiopsy Multiparametric Magnetic Resonance Imaging Compared with Biopsy.
Stonier T; Simson N; Shah T; Lobo N; Amer T; Lee SM; Bass E; Chau E; Grey A; McCartan N; Acher P; Ahmad I; Arumainayagam N; Brown D; Chapman A; Elf D; Hartington T; Ibrahim I; Leung H; Liyanage S; Lovegrove C; Malthouse T; Mateen B; Mistry K; Morrison I; Nalagatla S; Persad R; Pope A; Sokhi H; Syed H; Tadtayev S; Tharmaratnam M; Qteishat A; Miah S; Emberton M; Moore C; Walton T; Eddy B; Ahmed HU
Eur Urol Focus; 2021 Sep; 7(5):1027-1034. PubMed ID: 33046412
[TBL] [Abstract][Full Text] [Related]
19. Validation of IMPROD biparametric MRI in men with clinically suspected prostate cancer: A prospective multi-institutional trial.
Jambor I; Verho J; Ettala O; Knaapila J; Taimen P; Syvänen KT; Kiviniemi A; Kähkönen E; Perez IM; Seppänen M; Rannikko A; Oksanen O; Riikonen J; Vimpeli SM; Kauko T; Merisaari H; Kallajoki M; Mirtti T; Lamminen T; Saunavaara J; Aronen HJ; Boström PJ
PLoS Med; 2019 Jun; 16(6):e1002813. PubMed ID: 31158230
[TBL] [Abstract][Full Text] [Related]
20. Development of a nomogram combining multiparametric magnetic resonance imaging and PSA-related parameters to enhance the detection of clinically significant cancer across different region.
Zhou Z; Liang Z; Zuo Y; Zhou Y; Yan W; Wu X; Ji Z; Li H; Hu M; Ma L
Prostate; 2022 Apr; 82(5):556-565. PubMed ID: 35098557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
